ArticleCureus2026
Systemic Treatment of Metastatic Sertoli Cell Tumor.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 52-year-old man with a metastatic right testicular Sertoli cell tumor. The patient presented with fatigue, anorexia, unintentional weight loss, and bilateral gynecomastia. Staging computed tomography revealed pleural, hepatic, and bone metastases. Laboratory evaluation demonstrated markedly elevated estradiol and testosterone levels with suppressed gonadotropins. Histopathological analysis of a metastatic soft-tissue lesion confirmed the diagnosis. A multidisciplinary approach combining BEP (bleomycin, etoposide, and cisplatin) chemotherapy with hormonal therapy using letrozole and goserelin was initiated. Despite treatment, disease progression was observed, and enrollment in a clinical trial was considered. The patient ultimately died one month later due to respiratory failure. This case highlights the aggressive behavior of metastatic Sertoli cell tumors and underscores the challenges in managing rare, hormone-producing, treatment-refractory testicular neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.